TVMR With the Innovalve System Trial - First In Human Israel

Last updated: April 18, 2025
Sponsor: Edwards Lifesciences
Overall Status: Completed

Phase

N/A

Condition

Mitral Valve Regurgitation

Treatment

Innovalve MR system

Clinical Study ID

NCT05688514
INVL20-01-IL
  • Ages > 18
  • All Genders

Study Summary

Study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinically significant, symptomatic mitral regurgitation

  • High risk for open-heart surgery

  • Meets anatomical criteria

Exclusion

Exclusion Criteria:

  • Unsuitable anatomy

  • Patient is inoperable

  • EF<25%

Study Design

Total Participants: 1
Treatment Group(s): 1
Primary Treatment: Innovalve MR system
Phase:
Study Start date:
October 01, 2021
Estimated Completion Date:
April 01, 2025

Study Description

The study is a multi-center, First-In-Human, prospective, single arm early feasibility study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Connect with a study center

  • The Chaim Sheba Medical Center

    Ramat Gan, 5265601
    Israel

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.